Vir Biotechnology Secures Breakthrough Designations for Chronic Hepatitis Delta Treatments

Vir Biotechnology Advances Chronic Hepatitis Delta Treatments with Regulatory Designations

Vir Biotechnology, Inc. has achieved significant milestones in the development of its therapies, tobevibart and elebsiran, for chronic hepatitis delta (CHD). Recently, both treatments received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). These recognitions stem from promising safety and efficacy results presented during the Phase 2 SOLSTICE trial at AASLD The Liver Meeting® in San Diego. This groundbreaking research highlights the potential of these therapies to address an urgent medical need, as there are currently no approved treatments for CHD in the U.S., and very limited options available in Europe and globally.

The SOLSTICE trial is a multi-center, open-label study that evaluates the safety and effectiveness of tobevibart and elebsiran in patients suffering from CHD. The results indicate that this combination therapy can significantly suppress the hepatitis delta virus, achieving undetectable levels in participants. Mark Eisner, M.D., M.P.H., Chief Medical Officer of Vir Biotechnology, emphasizes that the data from the trial showcases the urgent requirement for effective therapeutic options for this severe liver disease, which can result in liver cancer and rapid progression to cirrhosis and liver failure within five years of infection. The Phase 3 ECLIPSE registrational program is expected to commence in the first half of 2025, further solidifying the therapeutic potential of these treatments.

The FDA's Breakthrough Therapy designation and the EMA's PRIME designation not only validate the promising results of the SOLSTICE trial but also facilitate a more streamlined regulatory process for Vir Biotechnology. These designations aim to expedite the development of therapies for serious conditions with unmet medical needs, ensuring early engagement with regulatory agencies to enhance data collection and accelerate marketing authorization applications. Earlier this year, the therapies also received FDA Fast Track designation and a positive opinion from the EMA’s Committee for Orphan Medicinal Products, indicating strong momentum for their clinical development.

In the landscape of liver diseases, CHD poses a significant challenge due to the lack of effective treatments. Vir Biotechnology's advancements in this area represent a potential breakthrough for patients affected by this severe condition. The ongoing commitment to research and development underscores the company’s dedication to addressing critical health needs and improving patient outcomes in the field of infectious diseases. As the Phase 3 trials approach, the healthcare community remains optimistic about the future of CHD treatment options.